HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Post‐transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA‐identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Giorgia Battipaglia Myriam Labopin Rose‐marie Hamladji Didier Blaise 1 Patrice Chevallier Eolia Brissot Armin Gerbitz Gerard Socié Boris Afanasyev Fabio Ciceri Ellen Meijer Yener Koc Jan Cornelissen Anne Huynh Hakan Ozdogu Johan Maertens Franciane Paul 2 Hélène Labussière‐wallet Annalisa Ruggeri Mahmoud Aljurf Ali Bazarbachi Bipin Savani Arnon Nagler Mohamad Mohty
1 CRCM - Centre de Recherche en Cancérologie de Marseille
2 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
Abstract : Background: Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Addition of antithymocyte globulin (ATG) or post-transplantation cyclophosphamide (PTCY) to standard immunosuppressive agents reduces GVHD in different donor settings. Methods: We compared the outcomes of adults with acute myeloid leukemia undergoing allo-HSCT from HLA-identical sibling donors after the use of PTCY (n = 197) or ATG (n = 1913). Results: Patients in the PTCY group were younger than those in the ATG group (median age, 47 vs 54 years; P < .01). Peripheral blood was the most frequently used stem cell source, being significantly more frequent in the ATG group than in the PTCY group (95% vs 70% P < .01). The conditioning regimen was more frequently myeloablative in the PTCY group than in the ATG group (59% vs 48%; P < .01). Time to neutrophil engraftment was shorter in the ATG group than in the PTCY group (17 vs 20 days; P < .01). No differences were observed according to the other transplantation outcomes, except for chronic GVHD of all grades and extensive chronic GVHD at 2 years, which were significantly lower in the ATG group compared with the PTCY group (P < .02). Conclusion: PTCY is feasible in an HLA-identical sibling setting, and despite similar outcomes, ATG may be associated with lower incidence of chronic GVHD.
Keywords : acute myeloid leukemia allogeneic hematopoietic transplantation antithymocyte globulin graft-versus-host disease post-transplantation cyclophosphamide
Document type :
Journal articles
Complete list of metadata
https://hal-amu.archives-ouvertes.fr/hal-03152844
Contributor : Jacques Nunès Connect in order to contact the contributor
Submitted on : Thursday, February 25, 2021 - 8:27:27 PM
Last modification on : Thursday, May 19, 2022 - 5:32:31 PM

Identifiers

Collections

UNIV-AMU | CRCM | CNRS

Citation

Giorgia Battipaglia, Myriam Labopin, Rose‐marie Hamladji, Didier Blaise, Patrice Chevallier, et al.. Post‐transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA‐identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, Wiley, 2021, 127 (2), pp.209-218. ⟨10.1002/cncr.33255⟩. ⟨hal-03152844⟩

Export

BibTeX TEI DC DCterms EndNote Datacite

Share

Metrics

Record views

19